Amesite Inc. filed a Form 8-K to furnish presentation materials for the H.C. Wainwright 28th Annual Global Investment Conference scheduled for September 14–16, 2026. The attached shareholder update highlights the company's transition from its B2C NurseMagic app to enterprise LynkMagic solutions targeting post-acute care providers, financial management services, and healthcare REITs. Key metrics include a $389B addressable market for paying providers, pricing models ranging from $7.99 per clinician monthly to $1,099 per site monthly, and a 2026 Q2 revenue trajectory showing growth. The presentation references a $2.6 million capital raise completed in April 2026 at $1.435 per share, resulting in approximately $2.9 million in cash on hand with an estimated 16 months of runway. Amesite Inc. operates in the healthcare technology sector, building AI-powered enterprise software and documentation solutions for post-acute care organizations.

Amesite Inc. entered into an At The Market (ATM) Offering Agreement with H.C. Wainwright & Co., LLC on July 17, 2026, allowing the company to sell common stock through the agent to raise capital. The company will pay the agent a 3.0% commission on gross proceeds and will reimburse the Agent for certain legal and due diligence fees up to $50,000. Amesite Inc. is an artificial intelligence-driven education technology company.

At its annual meeting on July 13, 2026, Amesite Inc. stockholders approved an amendment to the 2018 Equity Incentive Plan to increase the available share pool and incentive stock option issuance capacity by 1,000,000 shares each. Shareholders also approved the issuance of 1,393,732 shares of common stock resulting from the exercise of Series A-1 and Series A-2 warrants, in compliance with Nasdaq Listing Rule 5635(d). Additionally, Ann Marie Sastry and Barbie Brewer were elected as Class II directors, and the appointment of Novogradac & Company LLP as independent auditor was ratified. Amesite Inc. is an artificial intelligence-driven education technology company.